[go: up one dir, main page]

KR920016444A - 이미다졸, 트리아졸 및 테트라졸 유도체 - Google Patents

이미다졸, 트리아졸 및 테트라졸 유도체 Download PDF

Info

Publication number
KR920016444A
KR920016444A KR1019920001592A KR920001592A KR920016444A KR 920016444 A KR920016444 A KR 920016444A KR 1019920001592 A KR1019920001592 A KR 1019920001592A KR 920001592 A KR920001592 A KR 920001592A KR 920016444 A KR920016444 A KR 920016444A
Authority
KR
South Korea
Prior art keywords
indol
formula
group
ylmethyl
ethylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019920001592A
Other languages
English (en)
Other versions
KR100212111B1 (ko
Inventor
베이커 레이몬드
지. 매타사 빅터
스트리트 레슬리 제이
Original Assignee
앨런 허스케쓰
머크 샤프 앤드 돔 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920016444(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919102222A external-priority patent/GB9102222D0/en
Priority claimed from GB919106917A external-priority patent/GB9106917D0/en
Priority claimed from GB919113415A external-priority patent/GB9113415D0/en
Priority claimed from GB919122451A external-priority patent/GB9122451D0/en
Application filed by 앨런 허스케쓰, 머크 샤프 앤드 돔 리미티드 filed Critical 앨런 허스케쓰
Publication of KR920016444A publication Critical patent/KR920016444A/ko
Application granted granted Critical
Publication of KR100212111B1 publication Critical patent/KR100212111B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Paints Or Removers (AREA)
  • Lubricants (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Dental Preparations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Steroid Compounds (AREA)

Abstract

내용 없음

Description

이미다졸, 트리아졸 및 테트라졸 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 일반식(Ⅰ)의 화합물, 또는 이의 염 또는 예비약제.
    (Ⅰ)
    상기식에서, 점선은 5원환의 임의의 위치에 존재하는 두개의 비-인접한 이중 결합을 나타내고, V, W, X, Y, 및Z는 이들중 두개 내지 네개는 질소이고 나머지는 탄소이며, 단, 이들중 두개가 질소이고 나머지가 탄소인 경우에, 상기한 두개의 질소원자들은 5원환중 비-인접한 위치에 존재하며, A1은 수소, 탄화수소, 헤테로사이클릭그룹, 할로겐, 시아노,트리플루오로메틸, 또는 일반식 ORx, -SRx,-NRxRy, -NRxCORy, -NRxCO2Ry, -NRxSO2Ry또는 -NRxCTNRxRy[여기서, Rx및Ry는 독립적으로 수소, 탄화수소 또는 헤테로사이클릭 그룹을 나타내거나, 이들은 함께 C2-6알킬렌 그룹을 형성하며;Rx는 수소, 탄화수소 또는 헤테로사이클릭 그룹이고;T는 산소, 황 또는 일반식=NG(여기서, G는 탄화수소, 헤테로사이클릭 그룹 또는 전자-구성인 그룹이다)의 그룹이다]의 그룹이고, A2는 V,W,X,Y,및 Z중 네개가 질소이고 다른 하나가 탄소일 경우에는 비-결합된 전자쌍이고, V,W,X,Y및Z중 두개 또는 세개가 질소이고 나머지가 탄소일 경우에는 수소, 탄화수소, 헤테로사이클릭 그룹, 할로겐, 시아노, 트리플루오로메틸, 또는 일반식ORx, -SRx, -NRxRy,-NRxCORy, -NRxCO2Ry, -NRxSO2Ry또는 -NRxCTNRxRy(여기서, Rx,Ry,Rx및 T는 A1에 대해서 상기한 바와 같다)의 그룹이며, E는 하나의 결합 또는 탄소수 1내지 4의 직쇄 또는 측쇄 알킬렌쇄이고,
    F는 일반식[여기서, U는 질소 또는 C-R2이고;B는 산소, 황
    또는 N-R3이며;R1은 -CH2CHR4NR6R7또는 일반식
    또는의 그룹이고;R2,R3,R4,R5,R6및 R7은 독립적으로 수소 또는 C1-6
    알킬이다]의 그룹이다.
  2. 제1항에 있어서, 일반식(ⅡA)의 화합물, 및 이의 염 및 예비 약제.
    상기식에서, X1질소 또는 A12-C이고, n은 0,1,2또는 3이며, B1은 산소, 황 또는 N-R13이고, A11및 A12는 독립적으로 임의로 치환될수 있는 C1-6알킬, C2-6알케닐, C2-6알키닐, C3-7사이클로알킬, 아릴, 아릴(C1-6)알킬, C3-7헤테로사이클로알킬, 헤테로알킬, 헤테로아릴 또는 헤테로아릴(C1-6)알킬;또는 수소, 할로겐, 시아노, 트리플루오로메틸, C1-6알콕시, C1-6알킬티오 또는 일반식-NRxRy(여기서, Rx및Ry는 독립적으로 수소, 탄화수소 또는 헤테로사이클릭 그룹이거나, 이들은 함께 C2-6알킬렌 그룹을 형성한다)의 그룹이며, R12,R13,R14,R16,및R17은 독립적으로 수소 또는 C1-6알킬이다.
  3. 제1항에 있어서, 일반식(ⅡB)의 화합물, 및 이의 염 및 예비약제.
    상기식에서, Y1질소 또는 A22-C이고, n은 0,1,2또는 3이며, B2는 산소, 황 또는 N-R23이고, A21및A22는 독립적으로 임의로 치환될 수 있는 C1-5알킬, C2-6알케닐, C2-6알키닐, C3-7사이클로알킬, 아릴, 아릴(C1-6)알킬, C3-7헤테로사이클로알킬, 헤테로아릴 또는 헤테로아릴(C1-6)알킬;또는 수소, 할로겐, 시아노, 트리플루오로메틸, C1-6알콕시, C1-6알킬티오 또는 일반식-NRxRy(여기서, Rx및Ry는 독립적으로 수소, 탄화수소 또는 헤테로사이클릭 그룹을 나타내거나, 이들은 함께 C2-6알킬렌 그룹을 형성하다)의 그룹이며, R23,R23,R24,R26및R27은 독립적으로 수소 또는 C1-6알킬이다.
  4. 제1항에 있어서, 일반식(ⅡC)의 화합물, 및 이의 염 및 예비약제.
    상기식에서, Y2은 질소 또는A32-C이고, Z1은 질소 또는 CH이며, n은 0,1,2또는 3이고, B3는 산소, 황 또는 N-R33이고, A31및 A32는 독립적으로 임의로 치환될 수 있는 C1-6알킬, C2-6알케닐, C2-6알키닐, C3-7사이클로알킬, 아릴, 아릴(C1-6)알킬, C3-7헤테로사이클로알킬, 헤테로아릴 또는 헤테로아릴(C1-6)알킬;또는 수소, 할로겐, 시아노, 트리플루오로메틸, C1-6알콕시, C1-6알킬티오 또는 일반식 -NRxRy(여기서, Rx및 Ry는 독립적으로 수소, 탄화수소 또는 헤테로사이클릭 그룹을 나타내거나, 이들은 함께 C2-6알킬렌 그룹을 형성한다)의 그룹이며, R31은 일반식 -CH2CHR34NR36R37의 그룹 또는 일반식
    또는의 그룹이며
    R32,R33,R34,R35,R36및 R37은 독립적으로 수소 또는 C1-6알킬이다.
  5. 제1항에 있어서, 일반식(ⅡD)의 화합물, 및 이의 염 및 예비약제.
    상기식에서, W1은 질소 또는 C-A42이고, n은 0,1,2또는 3이며, B4는 산소, 황 또는 N-R43이고, A41및 A42는 독립적으로 임의로 치환될 수 있는 C1-6알킬, C2-6알케닐, C2-6알키닐, C3-7사이클로알킬, 아릴, 아릴(C1-6)알킬, C3-7헤테로사이클로알킬, 헤테로아릴 또는 헤테로아릴(C1-6)알킬;또는 수소, 할로겐, 시아노, 트리플루오로메틸, C1-6알콕시, C1-6알킬티오 또는 일반식-NRxRy(여기서,Rx및 Ry는 독립적으로 수소, 탄화수소 또는 헤테로사이클릭 그룹이거나, 이들은 함께 C2-6알킬렌 그룹을 형성한다)의 그룹이며, R41은 일반식 -CH2CHR44NR46R47의 그룹 또는 일반식
    또는의 그룹이고
    R42,R43,R44,R45,R46및R47은 독립적으로 수소 또는 C1-6알킬이다.
  6. 제1항에 있어서, 2-[5-(2-벤질테트라졸-5-일메틸)-1H-인돌-3-일]에틸아민;2-[5-(1-벤질테트라졸-5-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(1-메틸테트라졸-5-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(2-메틸테트라졸-5-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(1,2,4-트리아-1-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(테트라졸-2-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(테트라졸-1-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(1-메틸-1,2,4-트라아졸-5-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(1-메틸-1,2,4-트리아졸-3-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(1,2,3-트리아졸-1-일메틸)-1H-인돌-3-일]에틸아민;3-(2-아미노에틸)-5-(1-메틸테트라졸-5-일)벤조[b]티오펜;3-(2-아미노에틸)-5-(2-메틸테트라졸-5-일)벤조[b]티오펜;3-[2-(N,N-디메틸아미노)에틸]-5-(2-메틸테트라졸-5-일)벤조[b]티오펜;N,N-디메틸-2-[5-(2-메틸이미다졸-1-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(이미다졸-1-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(2-메틸이미다졸-1-일)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(2-에틸테트라졸-5-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(1-에틸테트라졸-5-일메틸)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(1,2,4-트리아졸-1-일)-1H-인돌-3-일]에틸아민;1-메틸-4-[5-(2-메틸이미다졸-1-일)-1H-인돌-3-일]피페리딘;1-메틸-4-[5-(1,2,4-트리아졸-1-일메틸)-1H-인돌-3-일]피페리딘;4-[5-(2-메틸이미다졸-1-일)-1H-인돌-3-일]피페리딘;4-[5-(1,2,4-트리아졸-1-일메틸)-1H-인돌-3-일]피페리딘;3-[5-(2-메틸이미다졸-1-일)-1H-인돌-3-일]피롤리딘;1-메틸-3-[5-(2-메틸이미다졸-1-일)-1H-인돌-3-일]피롤리딘;4-[5-(이미다졸-1-일)-1H-인돌-3-일]피페리딘;4-[5-(1,2,3-트리아졸-1-일)-1H-인돌-3-일]피페리딘;1-메틸-4-[5-(이미다졸-1-일)-1H-인돌-3-일]피페리딘;1-메틸-4-[5-(1,2,3-트리아졸-1-일)-1H-인돌-3-일]피페리딘;1-메틸-3-[5-(1,2,3-트리아졸-1-일)-1H-인돌-3-일]피페리딘;1-메틸-3-[5-(2-메틸이미다졸-1-일메틸)-1H-인돌-3-일]피롤리딘;1-메틸-3-[5-(이미다졸-1-일)-1H-인돌-3-일]피롤리딘;1-메틸-3-[5-(1,2,4-트리아졸-1-일메틸)-1H-인돌-3-일]피롤리딘;1-메틸-3-[5-(이미다졸-1-이메틸)-1H-인돌-3-일]피롤리딘;N,N-디메틸-2-[5-(2-아미노이미다졸-1-일)-1H-인돌-3-일]에틸아민;N,N-디메틸-2-[5-(2-아미노이미다졸-1-일메틸)-1H-인돌-3-일]에틸아민;N-메틸-2-[5-(1,2,4-트리아졸-1-일메틸)-1H-인돌-3-일]에틸아민;및 이들의 염 및 예비약제중에서 선택된 화합물.
  7. 제1항 내지 제6항 중 어는 한 항에 따른 화합물을 약제학적으로 허용되는 담체 또는 부형제와 혼합된 상태로 포함하는 약제학적 조성물.
  8. 치료학적 용도로 사용하기 위한 제1항 내지 제6항 중 어느 한 항에 따른 화합물.
  9. 5-HT1-형 수용체의 선택적 효능제가 요구되는 임상적 질환을 치료하고/하거나 예방하기 위한 약제를 제조하기 위한 제1항 내지 6항 중 어느 한 항에 따른 화합물의 용도.
  10. (A)일반식(Ⅲ')의 카복실산의 반응성 유도체를 일반식(Ⅲ)또는 (Ⅳ)의 화합물 또는 이의 염과 반응시키거나, (B)일반식(ⅩⅣ)의 화합물을 음이온 A2-(여기서, A2는 제1항에서 정의한 바와 같다)을 제공하는 시약과 반응시키거나, (C)일반식(Ⅲ")의 알킨을 일반식(Ⅲ"')의 아지드로 사이클로부가반응시키거나, (D)일반식(Ⅳ')의 니트릴을 일반식(Ⅳ")의 아지드로 사이클로부가반응시키거나, (E)일반식(Ⅳ"')의 화합물을 염기의 존재하에서 일반식(XV)의 테트라졸 유도체와 반응시키거나, (F)일반식(Ⅴ')으 니트릴을 아지드화나트륨으로 사이클로부가반응시킨 후 무기산으로 산성화시키거나, (G) 일반식(X Ⅵ)의 화합물을 일반식(Ⅶ)의 화합물 또는 이의 카보닐-보호된 형태의 화합물과 반응시키고, 경우에 따라 표준 방법으로 N-알킬화시켜 잔기R3을 도입시키거나, (H)일반식(XXⅡ)의 화합물을 폐환반응시키고, 경우에 따라 표준방법으로 N-알킬화시켜 잔기R3을 도입시키거나,(I)일반식(XXV)의 화합물을 폐환반응시키고, 경우에 따라 그룹R21을 목적하는 그룹R1으로 전환시키고, (J)계속해서, 경우에 따라, 최초로 수득된 일반식(Ⅰ)의 화합물을 통상의 방법으로 다른 일반식(Ⅰ)의 화합물로 전환시킴을 특징으로 하여, 제1항 내지 제6항 중 어느 한 항에 따른 화합물을 제조하는 방법.
    (Ⅰ)
    Ra-CO2H (Ⅲ')
    (Ⅲ)
    (Ⅳ)
    (XⅣ)
    Ra-C=C-Rb(Ⅲ")
    Rc-N3(Ⅲ"')
    N=C-Rd(Ⅳ')
    Re-N3(Ⅳ")
    Re-L (Ⅳ"')
    N≡C-E-F
    상기식에서,A1,A2,E,F,V,W,X,Y,Z 및 점선은 제1항에서 정의한 바와 같고, Ra,Rb및 Rc는 이들중 하나는 일반식 A1의 그룹이고, 다른 하나는 일반식A2의 그룹이며,또다른 하나는 일반식 -E-F의 그룹이고, Rd및Re는 이들 중 하나는 일반식 A1의 그룹이며, 다른 하나는 일반식 -E-F의 그룹이고, Hal은 할로겐을 나타내며, Va,Wa,Xa,Ya및Za는 이들 중 두개의 그룹은 탄소이고 나머지는 질소이며, 이들중 하나에 그룹 Hal이 결합되어 있으며, R11은 제1항에서 정의한 그룹 R1에 상응하거나, 일반식-CH2CHR4D1(여기서, R4는 제1항에서 정의한 바와같고, D1은 용이하게 치환시킬 수 있는 그룹이다)의 그룹이고, D2는 용이하게 치환시킬 수 있는 그룹이며, Ba는 산소 또는 황이고, R21은 제1항에서 정의한 바와 같은 그룹 R1에 상응하거나 이의 전구체그룹을 나타낸다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920001592A 1991-02-01 1992-02-01 이미다졸, 트리아졸 및 테트라졸 유도체, 및 이를 포함하는 약제학적 조성물 Expired - Lifetime KR100212111B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB9102222.8 1991-02-01
GB919102222A GB9102222D0 (en) 1991-02-01 1991-02-01 Therapeutic agents
GB9106917.9 1991-04-03
GB919106917A GB9106917D0 (en) 1991-04-03 1991-04-03 Therapeutic agents
GB9113415.5 1991-06-21
GB919113415A GB9113415D0 (en) 1991-06-21 1991-06-21 Therapeutic agents
GB9122451.9 1991-10-23
GB919122451A GB9122451D0 (en) 1991-10-23 1991-10-23 Therapeutic agents

Publications (2)

Publication Number Publication Date
KR920016444A true KR920016444A (ko) 1992-09-24
KR100212111B1 KR100212111B1 (ko) 1999-08-02

Family

ID=27450619

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920001592A Expired - Lifetime KR100212111B1 (ko) 1991-02-01 1992-02-01 이미다졸, 트리아졸 및 테트라졸 유도체, 및 이를 포함하는 약제학적 조성물

Country Status (30)

Country Link
US (4) US5298520A (ko)
EP (2) EP0497512B1 (ko)
JP (1) JP2500280B2 (ko)
KR (1) KR100212111B1 (ko)
CN (4) CN1038681C (ko)
AT (1) ATE158582T1 (ko)
BG (1) BG62024B2 (ko)
CA (2) CA2060139C (ko)
CY (1) CY2095B1 (ko)
CZ (1) CZ283018B6 (ko)
DE (2) DE69222329T2 (ko)
DK (1) DK0497512T3 (ko)
ES (2) ES2162188T3 (ko)
FI (1) FI107154B (ko)
GR (2) GR3025026T3 (ko)
HR (1) HRP930777B1 (ko)
HU (2) HU222350B1 (ko)
IE (1) IE920342A1 (ko)
IL (1) IL100756A (ko)
LU (1) LU90338I2 (ko)
LV (1) LV12090B (ko)
MX (1) MX9200405A (ko)
NL (1) NL980019I1 (ko)
NO (2) NO180447C (ko)
NZ (1) NZ241394A (ko)
SA (1) SA94140534B1 (ko)
SG (1) SG50409A1 (ko)
SI (1) SI9210101B (ko)
SK (1) SK278998B6 (ko)
YU (1) YU48236B (ko)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114690A (en) * 1990-06-07 1997-02-18 Wellcome Found Antimigraine oxazolidinone substituted indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
AU2363492A (en) * 1991-08-03 1993-03-02 Smithkline Beecham Plc 5-ht4 receptor antagonists
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
TW288010B (ko) * 1992-03-05 1996-10-11 Pfizer
EP0630374B1 (en) * 1992-03-13 2001-09-05 MERCK SHARP & DOHME LTD. Imidazole, triazole and tetrazole derivatives
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
CA2133413C (en) 1992-04-07 2001-04-10 John Eugene Macor Indole derivatives as 5-ht1 antagonists
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
US5498626A (en) * 1992-04-10 1996-03-12 Pfizer Inc. Acylaminoindole derivatives as 5-ht1 agonists
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208463D0 (en) * 1992-04-16 1992-06-03 Merck Sharp & Dohme Therapeutic agents
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
AU4337293A (en) * 1992-06-05 1994-01-04 Merck Sharp & Dohme Limited The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
GB9215526D0 (en) * 1992-07-22 1992-09-02 Merck Sharp & Dohme Chemical process
JPH07509452A (ja) * 1992-07-24 1995-10-19 メルク　シヤープ　エンド　ドーム　リミテツド イミダゾール，トリアゾール及びテトラゾール誘導体
IL106445A (en) * 1992-07-30 1998-01-04 Merck Sharp & Dohme History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
TW251284B (ko) * 1992-11-02 1995-07-11 Pfizer
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US6060473A (en) * 1993-04-01 2000-05-09 Ucb S.A. - Dtb 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
CZ59996A3 (en) * 1993-08-31 1996-06-12 Pfizer 5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon
CA2171440A1 (en) 1993-09-10 1995-03-16 Changgeng Qian Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
GB9402016D0 (en) * 1994-02-02 1994-03-30 Merck Sharp & Dohme Therapeutic agents
GB9402011D0 (en) * 1994-02-02 1994-03-30 Merck Sharp & Dohme Therapeutic agents
US6117889A (en) * 1994-04-01 2000-09-12 University Of Virginia 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents
US5552402A (en) * 1994-05-19 1996-09-03 Merck, Sharp & Dohme Ltd. Five-membered heteroaromatic compounds as 5-HT receptor agonists
US5807857A (en) * 1994-05-19 1998-09-15 Merck Sharp & Dohme Ltd. Piperazine, piperidine and tetrahydropyridine derivative of indol-3-alkyl as 5-HT1D-α agonists
GB9410031D0 (en) * 1994-05-19 1994-07-06 Merck Sharp & Dohme Therapeutic agents
US5567824A (en) * 1994-05-24 1996-10-22 Merck & Co., Inc. Palladium catalyzed ring closure of triazolyltryptamine
WO1996003400A1 (en) * 1994-07-26 1996-02-08 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
CA2195107A1 (en) * 1994-08-02 1996-02-15 Richard Alexander Jelley Azetidine, pyrrolidine and piperidine derivatives
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
US5484763A (en) * 1995-02-10 1996-01-16 American Cyanamid Company Substituted benzisoxazole and benzisothiazole herbicidal agents
NZ305166A (en) * 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
US5602168A (en) * 1995-07-10 1997-02-11 Neurogen Corporation 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands
US6245768B1 (en) 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US5656632A (en) * 1995-06-05 1997-08-12 Neurogen Corporation 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands
ATE207485T1 (de) * 1995-07-11 2001-11-15 Merck & Co Inc Ein triazolylmethyl-indol-ethylamin-bisulfat-salz
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
CA2234166A1 (en) * 1995-10-10 1997-04-17 Patric James Hahn N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
WO1997016446A1 (en) * 1995-11-02 1997-05-09 Merck Sharp & Dohme Limited Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation and their use as selective agonists of 5-ht1-like receptors
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
GB9610978D0 (en) * 1996-05-24 1996-07-31 Merck Sharp & Dohme Therapeutic agents
US5877329A (en) * 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
US5811551A (en) * 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
US5808064A (en) * 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
DE59710447D1 (de) 1996-08-19 2003-08-21 Volkswagen Ag FREMDGEZÜNDETE BRENNKRAFTMASCHINE MIT EINEM NOx-ADSORBER
WO1998007504A1 (de) 1996-08-19 1998-02-26 Volkswagen Aktiengesellschaft NOx-ABSORBER
GB9620777D0 (en) * 1996-10-07 1996-11-20 Merck Sharp & Dohme Therapeutic use
US5998438A (en) * 1996-11-26 1999-12-07 Allelix Biopharmaceuticals, Inc. 5-cyclo indole compounds
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
ZA991893B (en) * 1998-03-09 1999-09-27 Lundbeck & Co As H 5-Heteroaryl substituted indoles.
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK &amp; CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
CA2427098A1 (en) * 2000-11-29 2002-06-06 John Mehnert Schaus 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
US20030096379A1 (en) * 2001-03-28 2003-05-22 Kilgore James L. Method for producing tryptamine derivatives
DE10214228A1 (de) * 2002-03-22 2003-10-02 Bdd Group Holding Ag Zug Deuterierte substitutierte Indole sowie diese Verbindungen enthaltende Arzneimittel
WO2004000845A1 (en) 2002-06-21 2003-12-31 Suven Life Sciences Limited Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
JP4473120B2 (ja) 2002-06-21 2010-06-02 スベン ライフ サイエンシズ リミティド 治療薬剤として有用なセロトニン受容体親和性を有するアリールスルホニル・インドール、その製造方法、並びにそれらを含む医薬組成物
ES2204303B2 (es) * 2002-08-07 2004-12-16 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
EA009193B1 (ru) 2002-11-28 2007-12-28 Сувен Лайф Сайенсиз Лимитед N-арилсульфонил-3-аминоалкоксииндолы
KR100818508B1 (ko) 2002-11-28 2008-03-31 수벤 라이프 사이언시스 리미티드 세로토닌 수용체 친화력을 가지는 엔-아릴술포닐-3-치환인돌, 그 제조방법 및 그를 포함하는 약제학적 조성물
DE60312226T2 (de) 2002-12-18 2007-11-15 Suven Life Sciences Ltd. Tetrazyklische 3-substituierte indole mit serotoninrezeptoraffinität
EP2666772B1 (en) 2002-12-20 2017-03-01 Basf Se Synthesis of amines and intermediates for the synthesis thereof
KR100572325B1 (ko) * 2003-12-17 2006-04-19 삼성전자주식회사 이온 주입 장치 및 이를 이용한 이온 주입 방법
CA2552663A1 (en) * 2004-01-09 2005-07-28 Ratiopharm Gmbh Crystalline forms of rizatriptan benzoate
DK1751104T3 (da) * 2004-01-28 2010-06-07 Ratiopharm Gmbh Syntesemetoder og mellemprodukter til fremstilling af rizatriptan
WO2006053116A2 (en) * 2004-11-10 2006-05-18 Dr. Reddy's Laboratories Ltd. Rizatriptan process
MX2007005940A (es) * 2004-11-18 2007-06-19 Synta Pharmaceuticals Corp Compuestos de triazol que modulan la actividad hsp90.
WO2006082598A2 (en) * 2005-02-01 2006-08-10 Natco Pharma Limited Novel crystalline forms of rizatriptan benzoate
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
ES2270717B1 (es) * 2005-08-08 2008-03-01 Ragactives, S.L. Procedimiento para la obtencion de derivados de triptamina.
CA2618586A1 (en) * 2005-08-11 2007-02-15 Merck Frosst Canada Ltd. Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors
WO2007094819A2 (en) * 2005-08-18 2007-08-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP1951713A1 (en) * 2005-11-14 2008-08-06 Matrix Laboratories Ltd Process for the large scale production of rizatriptan benzoate
US20110313171A1 (en) 2006-01-19 2011-12-22 Chandra Purna Ray Conversion of aromatic diazonium salt to aryl hydrazine
WO2007139960A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
RS53446B (en) 2006-05-25 2014-12-31 Synta Pharmaceuticals Corp. TRIAZOLE UNITS MODULATING HSP90 ACTIVITY
US8318790B2 (en) * 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
CA2653332A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
ES2524556T3 (es) 2006-10-09 2014-12-10 Charleston Laboratories, Inc. Composiciones farmacéuticas
WO2008149152A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
WO2009049030A1 (en) * 2007-10-09 2009-04-16 Triton Biopharma, Llc Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
US20090294028A1 (en) * 2008-06-03 2009-12-03 Nanochip, Inc. Process for fabricating high density storage device with high-temperature media
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US20110082450A1 (en) * 2009-10-02 2011-04-07 Cardiofocus, Inc. Cardiac ablation system with inflatable member having multiple inflation settings
HUE030794T2 (en) * 2010-02-08 2017-06-28 Medivation Technologies Inc Synthesis Processes of Dihydro-Pyrido-Phthalazinone Derivatives
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
EP2780010A1 (en) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013120045A1 (en) 2012-02-10 2013-08-15 University Of Utah Research Foundation Substituted 1h-indazol-1-ol analogs as inhibitors of beta catenin/tcf protein-protein interactions
CN103739594A (zh) * 2012-10-17 2014-04-23 南京大学 一类含吡嗪环和三氮唑结构的席夫碱类衍生物及其制法
WO2016187308A1 (en) 2015-05-20 2016-11-24 Amgen Inc. Triazole agonists of the apj receptor
US20170119738A1 (en) * 2015-10-28 2017-05-04 Dr. Reddy's Laboratories, Ltd. Pharmaceutical compositions for rizatriptan
EP3407869A1 (en) 2016-01-27 2018-12-05 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2017189893A1 (en) 2016-04-27 2017-11-02 University Of Puerto Rico 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3475437A (en) * 1964-06-05 1969-10-28 Boehringer Sohn Ingelheim 3-tertiary amino lower alkylpseudoindoles
GB1237008A (en) * 1968-12-18 1971-06-30 Pfizer Ltd Novel indoline derivatives
US3686213A (en) * 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
DE2520816C3 (de) * 1975-05-09 1979-02-15 Bayer Ag, 5090 Leverkusen Methinfarbstoffe
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
IE51491B1 (en) * 1980-08-12 1987-01-07 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
GB2083463B (en) * 1980-08-12 1984-05-10 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
US4453001A (en) * 1982-02-22 1984-06-05 Sandoz, Inc. Isoxazolyl indolamines as intermediates
JPS58150576A (ja) * 1982-03-03 1983-09-07 Sumitomo Chem Co Ltd 新規な１，２，４−オキサジアゾ−ル誘導体
US4692531A (en) * 1984-06-22 1987-09-08 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
US4663526A (en) * 1984-12-26 1987-05-05 Emil Kamieniecki Nondestructive readout of a latent electrostatic image formed on an insulating material
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
EP0225726B1 (en) * 1985-11-08 1991-04-17 Glaxo Group Limited Indole derivatives
GB8527619D0 (en) * 1985-11-08 1985-12-11 Glaxo Group Ltd Chemical compounds
US4881967A (en) * 1986-12-10 1989-11-21 E. I. Du Pont De Nemours And Company Heterocyclic 2,3-dihydrobenzofuran herbicides
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
US5225431A (en) * 1987-10-23 1993-07-06 Burroughs Wellcome Co. Therapeutic substituted indole compounds and compositions thereof
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
IL114690A (en) * 1990-06-07 1997-02-18 Wellcome Found Antimigraine oxazolidinone substituted indole derivatives
AU2363492A (en) * 1991-08-03 1993-03-02 Smithkline Beecham Plc 5-ht4 receptor antagonists
KR930011238A (ko) * 1991-11-12 1993-06-24 오리 노리오 스태틱 알에이엠(ram)의 메모리셀 및 그 메모리셀어레이
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents

Also Published As

Publication number Publication date
NL980019I1 (nl) 1998-08-03
LV12090B (en) 1998-09-20
AU1068092A (en) 1992-08-06
HU9200299D0 (en) 1992-04-28
CS19892A3 (en) 1992-08-12
ES2162188T3 (es) 2001-12-16
HUT61013A (en) 1992-11-30
CN1157821A (zh) 1997-08-27
CA2238140C (en) 2002-06-18
KR100212111B1 (ko) 1999-08-02
CA2238140A1 (en) 1992-08-02
SA94140534B1 (ar) 2006-05-15
YU10192A (sh) 1995-03-27
NO920424D0 (no) 1992-01-31
HRP930777A2 (en) 1997-10-31
AU644939B2 (en) 1993-12-23
CA2060139A1 (en) 1992-08-02
NO920424L (no) 1992-08-03
SK278998B6 (sk) 1998-05-06
US5602162A (en) 1997-02-11
HU222350B1 (hu) 2003-06-28
EP0497512A3 (en) 1992-12-16
JP2500280B2 (ja) 1996-05-29
JPH05140151A (ja) 1993-06-08
GR3036864T3 (en) 2002-01-31
NO180447C (no) 1997-04-23
FI920442L (fi) 1992-08-02
HRP930777B1 (en) 2001-04-30
NO180447B (no) 1997-01-13
CY2095B1 (en) 2002-04-05
CN1061654C (zh) 2001-02-07
CN1128617C (zh) 2003-11-26
LV12090A (lv) 1998-07-20
CN1064485A (zh) 1992-09-16
CZ283018B6 (cs) 1997-12-17
ATE158582T1 (de) 1997-10-15
SG50409A1 (en) 1998-07-20
DE19975007I2 (de) 2004-08-12
IL100756A0 (en) 1992-09-06
US5451588A (en) 1995-09-19
NZ241394A (en) 1994-04-27
EP0497512A2 (en) 1992-08-05
US5602163A (en) 1997-02-11
CN1161967A (zh) 1997-10-15
CA2060139C (en) 1998-12-01
CN1161834A (zh) 1997-10-15
FI107154B (fi) 2001-06-15
LU90338I2 (fr) 1999-03-15
DE69222329T2 (de) 1998-04-09
SI9210101B (en) 2001-06-30
HU211516A9 (en) 1995-11-28
MX9200405A (es) 1992-08-01
IE920342A1 (en) 1992-08-12
SI9210101A (en) 1996-08-31
FI920442A0 (fi) 1992-01-31
BG62024B2 (bg) 1998-12-30
IL100756A (en) 1996-01-19
DE69222329D1 (de) 1997-10-30
EP0778275B1 (en) 2001-10-10
GR3025026T3 (en) 1998-01-30
US5298520A (en) 1994-03-29
YU48236B (sh) 1997-08-22
EP0778275A1 (en) 1997-06-11
CN1060479C (zh) 2001-01-10
CN1038681C (zh) 1998-06-10
EP0497512B1 (en) 1997-09-24
NO1999005I1 (no) 1999-04-09
ES2106822T3 (es) 1997-11-16
DK0497512T3 (da) 1997-10-27

Similar Documents

Publication Publication Date Title
KR920016444A (ko) 이미다졸, 트리아졸 및 테트라졸 유도체
US6962936B2 (en) Triazole-derived kinase inhibitors and uses thereof
KR100529423B1 (ko) 신경계 질환의 치료에 유용한 설포닐-피롤리딘 유도체
JP2019077725A5 (ko)
AU655544B2 (en) Azole compounds, their production and use
US7151182B2 (en) Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives
US20030208082A1 (en) Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
FI79103B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 1,4-dihydropyridinderivat.
AU656612B2 (en) 4(1-(H)-pyrrol-1-yl)imidazoles with angiotensin II antagonist activity
KR910014373A (ko) 인돌-치환된 5원 헤테로방향족 화합물
DE69717091T2 (de) Oxazole derivate,ihre herstellung und verwendung
ES2202453T3 (es) Agentes antifungicos de triazol.
EP0937072B1 (en) THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABA A alpha5 RECEPTOR SUBTYPE
HU211599A9 (en) Derivatives of benzimidazole and their use as antihistamines
US5140034A (en) Five-membered ring systems with bonded imidazolyl ring substituents
RU97115290A (ru) Соединения азола, способ получения указанных соединений и их применение
JP2965532B2 (ja) Ｎ−ベンジルアゾリウム誘導体
WO2001034578A1 (en) Compounds with anti-helicobacter pylori activity
KR930004674B1 (ko) 이미다졸 유도체와 그의 약학적 허용 가능한 에스테르, 아미드 및 염의 제조방법
KR20020087490A (ko) 1-(1ｈ-1,2,4-트리아졸-1-일)부탄-2-올 유도체
PT96165A (pt) Processo de preparacao de derivados do imidazole e de composicoes farmaceuticas que os contem
MX2008012952A (es) Moduladores heterociclicos del receptor selectivo del subtipo alfa de gaba.
RU98101110A (ru) Антигрибковые производные триазола
SI9300375B (sl) Derivati imidazola,triazola in tetrazola
KR20050042446A (ko) 신규 옥사졸리디논 유도체 및 그 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920201

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19970131

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920201

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19981128

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19990226

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19990507

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19990508

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20020427

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20030428

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20040430

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20050429

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20060502

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20070406

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20080407

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20090424

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20100429

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20110428

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20110428

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20121109

Termination category: Expiration of duration